Browse PRAME

Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cell membrane
Domain -
Function

Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.

> Gene Ontology
 
Biological Process GO:0030522 intracellular receptor signaling pathway
GO:0048384 retinoic acid receptor signaling pathway
GO:0048385 regulation of retinoic acid receptor signaling pathway
GO:0048387 negative regulation of retinoic acid receptor signaling pathway
Molecular Function GO:0008134 transcription factor binding
GO:0035257 nuclear hormone receptor binding
GO:0042974 retinoic acid receptor binding
GO:0051427 hormone receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRAME and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PRAME and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28630682Uterine carcinosarcoma; synovial sarcoma; multifocal leiomyosarcoma.Inhibit immunity (T cell function); resistant to immunotherapyWe found that uterine carcinosarcoma highly overexpresses the PRAME antigen, and synovial sarcomas and multifocal leiomyosarcomas also show high expressions suggesting that PRAME may be an effective target of immunotherapies of these tumors. However, we also discovered that PRAME expression negatively correlates with genes involved in antigen presentation, and in synovial sarcoma MHC class I antigen presentation deficiencies are also present, potentially limiting the efficacy of immunotherapies of this malignancy. Overexpression of PRAME negatively correlates to expression of genes in antigen presentation, and correlates to MHC class I antigen presentation deficiencies in synovial sarcoma.
23838315Childhood acute lymphoblastic leukemiaPromote immunity (T cell function); essential for immunotherapyPeripheral blood mononuclear cells were stimulated with autologous dendritic cells pulsed with complete peptide libraries of WT1, Survivin, MAGE-A3, and PRAME, antigens frequently expressed on ALL blasts. Antigen-specificity was observed in more than 50% of patients after the initial stimulation and increased to more than 90% after three stimulations as assessed in IFN-γ-enzyme-linked immunospot (ELISpot) and (51)Cr-release assays. This study supports the use of immunotherapy with adoptively transferred autologous tumor antigen-specific T cells to prevent relapse and improve the prognosis of patients with high-risk ALL.
29615432MedulloblastomaInhibit immunity (T cell function); immunotherapy targetAltogether, these data indicate that T cells genetically modified with a high-affinity, PRAME-specific TCR and iC9 may represent a promising innovative approach for treating HLA-A*02+ medulloblastoma patients.
18591381Chronic Myeloid LeukemiaImmunotherapy targetCytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
21771875MelanomaEssential for immunotherapyPRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. These T cells, however, also exerted low reactivity against mature dendritic cells (DC) and kidney epithelial cells, which was shown to be because of low PRAME expression.
16931630leukemiaPromote immunitySpecific T-cell responses were detected in 8 (47%) of 17 patients with AML in complete remission for RHAMM/HMMR-R3 peptide, in 7 (70%) of 10 for PRAME-P3 peptide, and in 6 (60%) of 10 for newly characterized G250/CA9-G2 peptide, a significant increased immune response compared with patients with AML patients who had refractory disease. In conclusion, expression of the TAAs RHAMM/HMMR, PRAME, and G250/CA9 can induce strong antileukemic immune responses, possibly enabling MRD control.
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRAME in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRAME in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4920.588
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1040.973
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.960.731
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1530.859
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4830.701
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2640.854
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.8780.0928
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.650.788
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11123.2460.221
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5750.74
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.070.976
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7230.155
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRAME in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRAME. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRAME. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRAME.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRAME. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRAME expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRAME and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRAME
Namepreferentially expressed antigen in melanoma
Aliases CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ......
Chromosomal Location22q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRAME collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.